Best Pharma & Healthcare Funds
Defensive-growth exposure to pharma, hospitals and diagnostics.
Data updated · 18 direct-growth funds ranked by a transparent 0–100 Smart Score
| ⚖ VS | Fund | Score ↓ | Verdict | 1Y | 3Y | 5Y | Sharpe | Sortino | Std Dev | Alpha | Beta | VR★ | P/E | Expense | AUM | Age |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma And Healthcare HDFC | 79 | Strong Buy | 28.9% | — | — | 1.83 | 2.63 | 14.0 | 21.2 | 0.66 | — | 49.8 | 1.11% | ₹2.9k Cr | 2.9y | |
| SBI Healthcare Opportunities SBI | 77 | Buy | 22.8% | 24.9% | 18.5% | 1.27 | 2.05 | 14.9 | 4.9 | 0.82 | — | 55.6 | 1.02% | ₹5.4k Cr | 13.7y | |
| UTI Healthcare UTI | 66 | Buy | 19.9% | 25.2% | 16.2% | 1.23 | 1.98 | 16.7 | 5.0 | 0.91 | — | 42.6 | 1.28% | ₹1.4k Cr | 13.7y | |
| Mirae Asset Healthcare Mirae Asset | 62 | Buy | 22.5% | 23.9% | 15.7% | 1.17 | 1.75 | 16.9 | 3.6 | 0.95 | — | 47.9 | 0.61% | ₹3.4k Cr | 8.2y | |
| Kotak Healthcare Kotak | 62 | Buy | 29.0% | — | — | 1.16 | 1.65 | 14.4 | 14.7 | 0.68 | — | 50.4 | 1.09% | ₹676 Cr | 2.7y | |
| ICICI Pru Healthcare ICICI Pru | 56 | Hold | 10.8% | 23.5% | 16.0% | 1.25 | — | 16.9 | 5.4 | 0.92 | — | — | 1.33% | ₹6.8k Cr | 8.2y | |
| DSP Healthcare DSP | 54 | Hold | 19.4% | 22.9% | 15.6% | 1.12 | 1.81 | 15.6 | 3.7 | 0.81 | — | 35.4 | 0.71% | ₹3.6k Cr | 7.8y | |
| PGIM India Healthcare PGIM India | 51 | Hold | 26.8% | — | — | 0.60 | 0.82 | 13.2 | 11.0 | 0.66 | — | 56.6 | 0.92% | ₹112 Cr | 1.8y | |
| Bajaj Finserv Healthcare Bajaj Finserv | 47 | Hold | 24.9% | — | — | 0.43 | 0.58 | 13.4 | 7.1 | 0.68 | — | 52.8 | 0.88% | ₹377 Cr | 1.7y | |
| ABSL Pharma And Healthcare Aditya Birla Sun Life | 46 | Hold | 20.3% | 23.0% | 14.4% | 1.15 | 1.86 | 16.2 | 3.1 | 0.91 | — | 47.6 | 1.01% | ₹1.1k Cr | 7.2y | |
| WhiteOak Capital Pharma And Heathcare WhiteOak | 45 | Hold | 24.4% | — | — | — | — | — | — | — | — | 51.3 | 1.16% | ₹825 Cr | 2.6y | |
| Nippon India Pharma Nippon India | 40 | Avoid | 14.1% | 19.6% | 13.7% | 1.02 | 1.46 | 13.0 | 9.5 | 0.59 | — | 40.4 | 1.00% | ₹9.3k Cr | 13.7y | |
| ITI Pharma And Healthcare ITI | 38 | Avoid | 15.2% | 20.9% | — | 1.02 | 1.42 | 14.2 | 10.1 | 0.67 | — | 47.6 | 0.98% | ₹263 Cr | 4.8y | |
| Baroda BNP Paribas Health And Wellness Baroda BNP Paribas | 37 | Avoid | 12.4% | — | — | 0.14 | 0.20 | 11.4 | 5.1 | 0.56 | — | 47.3 | 1.04% | ₹519 Cr | 1.2y | |
| Tata India Pharma & Healthcare Tata | 34 | Avoid | 11.8% | 21.1% | 14.7% | 1.05 | 1.56 | 17.2 | 0.6 | 0.97 | — | 44.7 | 0.97% | ₹1.5k Cr | 10.7y | |
| LIC MF Healthcare LIC | 32 | Avoid | 19.3% | 23.7% | 12.7% | 1.08 | 1.75 | 16.4 | 2.6 | 0.88 | — | 52.3 | 1.42% | ₹98 Cr | 7.5y | |
| Quant Healthcare Quant | 29 | Avoid | 24.6% | 22.1% | — | 0.89 | 1.24 | 17.4 | 9.7 | 0.92 | — | 41.2 | 1.51% | ₹389 Cr | 3.1y | |
| Bandhan Healthcare Bandhan | 22 | Avoid | — | — | — | — | — | — | — | — | — | 43.0 | 1.20% | ₹319 Cr | 0.8y |
Pharma & Healthcare funds — quick answers
›Which is the best Pharma & Healthcare mutual fund right now?
HDFC Pharma And Healthcare currently ranks #1 of 18 Pharma & Healthcare funds with a FundLens Smart Score of 79/100 (Strong Buy). It returned — over 3 years at a 1.11% expense ratio (direct plan). Rankings are recomputed from data updated 03 Sept 2026.
›Which Pharma & Healthcare fund has the best risk-adjusted returns?
HDFC Pharma And Healthcare leads the category on the Sortino ratio at 2.63 (Sharpe 1.83) — meaning it has delivered the most return per unit of downside risk among Pharma & Healthcare funds.
›Which Pharma & Healthcare fund has the lowest expense ratio?
Mirae Asset Healthcare charges 0.61% a year (direct plan) — the lowest in the category. Lower fees compound in your favour over long holding periods.
›Which is the smallest Pharma & Healthcare fund by AUM?
LIC MF Healthcare manages ₹98 Cr, the smallest in the category. Smaller funds can be nimbler, but check track record and costs before treating size alone as an edge.
›How long should I stay invested in a Pharma & Healthcare fund?
Pharma & Healthcare funds carry very high risk, so a horizon of 7+ years is generally sensible. Defensive-growth exposure to pharma, hospitals and diagnostics. This is research, not investment advice.
Want these answers conversationally? Ask FundLens · New to the ratios? Sharpe vs Sortino, explained